These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 1332581

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT, Yıldız K, Baysal B, Danalıoğlu A, Kocaman O, Tozlu M, Gangarapu V, Sarbay Kemik A, Uysal Ö, Şentürk H.
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B.
    Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
    [Abstract] [Full Text] [Related]

  • 29. Limits of CEA and ferritin in the diagnosis of pancreatic cancer.
    Plebani M, Fabris C, Basso D, Del Favero G, Angonese C, Leandro G, Di Mario F, Burlina A, Naccarato R.
    Int J Pancreatol; 1988 Sep; 3 Suppl 1():S113-7. PubMed ID: 3209864
    [Abstract] [Full Text] [Related]

  • 30. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
    van Dalen A, Kessler AC.
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F, Mischinger HJ.
    Anticancer Res; 1999 Apr; 19(1B):849-51. PubMed ID: 10216504
    [Abstract] [Full Text] [Related]

  • 33. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
    Mery CM, Duarte-Rojo A, Paz-Pineda F, Gómez E, Robles-Díaz G.
    Rev Invest Clin; 2001 Apr; 53(6):511-7. PubMed ID: 11921523
    [Abstract] [Full Text] [Related]

  • 34. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P, Boadas J, González-Carro P, Mora J, Pérez C, Martínez A, Roca M, Lluís F, Farré A.
    Gastroenterol Hepatol; 1999 Apr; 22(7):335-41. PubMed ID: 10535205
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Apr; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 36. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
    Fernández-Fernández L, Tejero E, Tieso A, Rabadán L, Munoz M, Santos I.
    Int Surg; 1996 Apr; 81(4):400-2. PubMed ID: 9127805
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K.
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [Abstract] [Full Text] [Related]

  • 38. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    J Cancer Res Clin Oncol; 1994 Aug; 120(8):494-7. PubMed ID: 8207049
    [Abstract] [Full Text] [Related]

  • 39. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
    Ial'chenko NA, Lagutin VD, Lavik NN, Musin II.
    Vopr Onkol; 1991 Aug; 37(9-10):921-4. PubMed ID: 1726842
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.